| Abstract | Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA. |
| Authors | E H Giannini, K S Barron, C H Spencer, D A Person, J Baum, B H Bernstein, D W Kredich, J C Jacobs, L S Zemel, D Gibbas
(Affiliation: Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229.)
|
| Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 18
Issue 8
Pg. 1240-2
(Aug 1991)
ISSN: 0315-162X CANADA |
| PMID | 1941832
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
|
| Topics |
- Administration, Oral
- Arthritis, Juvenile Rheumatoid
(drug therapy)
- Auranofin
(therapeutic use)
- Child
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Gold
(administration & dosage, therapeutic use)
- Humans
- Male
- Time Factors
|
